AC
ASBPW

Aristeia Capital’s Aspire Biopharma Warrant ASBPW Stock Holding History

Aristeia Capital’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Hold
681,516
– – ﹤0.01% 747
2026
Q1 		$12.4K Hold
681,516
– – ﹤0.01% 664
2025
Q4 		$13.4K Hold
681,516
– – ﹤0.01% 573
2025
Q3 		$19K Hold
681,516
– – ﹤0.01% 499
2025
Q2 		$30.6K Hold
681,516
– – ﹤0.01% 436
2025
Q1 		$49.8K Buy
+681,516
New +$41K ﹤0.01% 365

Other funds holding ASBPW

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Aristeia Capital's ASBPW Position: Q2 2026 in Review

Aristeia Capital held its Aspire Biopharma Warrant (ASBPW) position steady in Q2 2026 at 681,516 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #747.

Aristeia Capital first reported a position in ASBPW in Q1 2025 and has held it in 6 quarters since. The position peaked at $49.8K in Q1 2025. 27 funds tracked by Wall St. Rank hold ASBPW as of Q2 2026.

  • Aristeia Capital held 681,516 shares of Aspire Biopharma Warrant worth $15.9K as of Q2 2026.
  • Aristeia Capital left its Aspire Biopharma Warrant share count unchanged in Q2 2026.
  • Aspire Biopharma Warrant made up ﹤0.01% of Aristeia Capital's portfolio in Q2 2026, its #747 holding.
  • Aristeia Capital first reported a position in Aspire Biopharma Warrant in Q1 2025 and has held it in 6 quarters since.
  • Aristeia Capital's Aspire Biopharma Warrant position peaked at $49.8K in Q1 2025.
  • 27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.